Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PROSARC-2. Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. A Single-arm, Multicenter, Phase II Clinical Trial.

NCT07173972 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT07173972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07173972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PROSARC-2. Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. A Single-arm, Multicenter, Phase II Clinical Trial.
Lead sponsor
Oslo University Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
January 26, 2026
Completion date
November 1, 2035
Enrollment
40 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

leiomyosarcoma (lms), liposarcoma, myxofibrosarcoma, pleomorphic liposarcoma, pleomorphic rhabdomyosarcoma, soft tissue sarcoma (sts), soft tissue sarcoma adult, soft tissue sarcoma of the trunk and extremities, synovial sarcomas, undifferentiated pleomorphic sarcoma (ups)